Cetuximab conjugated TH (THC3) with intercalated doxorubicin (DOX) drug i.e. THDC3 (Table 1) showed preferential killing of MDA-MB-468 cancer cells, due to cetuximab which is known to target EGFR over-expressing cancer cells. This evidence concerns the gene EGFR and cancer.